Search

Displaying results 5731 - 5740 of 10000 in total
  1. Drug

    Seliciclib

    go.drugbank.com/drugs/DB06195
    Investigational

    R-roscovitine (Seliciclib or CYC202) is a cyclin-dependent kinase (CDK) inhibitor that preferentially inhibits multiple enzyme targets including CDK2, CDK7 and CDK9, which alter the growth phase of treated … Developed by Cyclacel, seliciclib is being researched for the treatment of non-small cell lung cancer (NSCLC), leukemia, HIV infection, herpes simplex infection, and the mechanisms of chronic inflammation

  2. Drug

    Piclidenoson

    go.drugbank.com/drugs/DB05511
    Investigational

    Its novel mechanism of action relies on antagonism of adenoside A3 receptors. CF101 is supplied as an oral drug and has an excellent safety profile. … It is also being considered for the treatment of other autoimmune-inflammatory disorders, such as Crohn's disease, psorasis and dry eye syndrome.

  3. Drug

    Telratolimod

    go.drugbank.com/drugs/DB19590
    Investigational

    Telratolimod has a monoisotopic molecular weight of 593.47 Da. … Telratolimod is under investigation in clinical trial NCT06680479 (Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living With HIV-1 on Suppressive Antiretroviral Therapy

  4. Drug

    Rezivertinib

    go.drugbank.com/drugs/DB21471
    Investigational

    Rezivertinib has a monoisotopic molecular weight of 486.24 Da. … Rezivertinib is under investigation in clinical trial NCT06955325 (Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations).

  5. Drug

    Opnurasib

    go.drugbank.com/drugs/DB21583
    Investigational

    Opnurasib has a monoisotopic molecular weight of 525.2 Da. … Opnurasib is under investigation in clinical trial NCT05132075 (Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer

  6. Drug

    Aluminium

    go.drugbank.com/drugs/DB01370
    ApprovedInvestigationalWithdrawn

    A metallic element that has the atomic number 13, atomic symbol Al, and atomic weight 26.98.

  7. Drug

    LIC-477

    go.drugbank.com/drugs/DB05363
    Experimental

    LIC-477is indicated to be suitable for the treatment of psychosomatic disturbances, epilepsy, trigeminal neuralgia and cerebral spasticity.

  8. Drug

    D-JNKI-1

    go.drugbank.com/drugs/DB05660
    Investigational

    organ of Corti during times of oxidative stress. … A synthetic, cell permeable peptide that blocks the MAPK-JNK signal pathway; has potential therapeutic value for long-term protection of both the morphological integrity and physiological function of the

  9. Drug

    PBI-1402

    go.drugbank.com/drugs/DB05480
    Experimental

    PBI-1402 appears to work on the PMN pathway, but its specific binding properties are not known. PBI-1402 has a dual therapeutic action; as a chemoprotectant and hematopoietic progenitor stimulator. … However, it has been shown that when co-administered with these compounds, effects are additive, making PBI-1402 an excellent candidate for combination therapy and asserting its independent mechanism of

  10. Drug

    Milatuzumab

    go.drugbank.com/drugs/DB12943
    Investigational

    Milatuzumab has been used in trials studying the treatment of Lupus Nephritis, Multiple Myeloma (MM), GVHD (Acute or Chronic), Myelodysplastic Syndrome, and Chronic Lymphocytic Leukemia, among others.